---
title: "Plus Therapeutics, Inc. (PSTV.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PSTV.US.md"
symbol: "PSTV.US"
name: "Plus Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T00:28:50.176Z"
locales:
  - [en](https://longbridge.com/en/quote/PSTV.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PSTV.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PSTV.US.md)
---

# Plus Therapeutics, Inc. (PSTV.US)

## Company Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [lustherapeutics.com](https://lustherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:15.000Z

**Overall: C (0.59)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 184 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.49% |  |
| Net Profit YoY | -72.49% |  |
| P/B Ratio | 9.32 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 37260806.61 |  |
| Revenue | 5213000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 903.94% | A |
| Profit Margin | -429.43% | E |
| Gross Margin | -60.73% | E |
| Revenue YoY | -10.49% | E |
| Net Profit YoY | -72.49% | E |
| Total Assets YoY | 146.12% | A |
| Net Assets YoY | 144.65% | A |
| Cash Flow Margin | 92.80% | C |
| OCF YoY | -10.49% | E |
| Turnover | 0.45 | C |
| Gearing Ratio | 75.52% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Plus Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.49%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-72.49%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "9.32",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "37260806.61",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5213000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "903.94%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-429.43%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-60.73%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.49%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-72.49%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "146.12%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "144.65%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "92.80%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-10.49%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.45",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "75.52%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.66 | 238/393 | - | - | - |
| PB | 9.32 | 383/393 | 17.34 | 14.22 | 9.88 |
| PS (TTM) | 7.15 | 136/393 | 13.31 | 8.59 | 2.90 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-09T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Overweight | 1 | 20% |
| Hold | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.65 |
| Highest Target | 475.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PSTV.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PSTV.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PSTV.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PSTV.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**